Unlocking the Power of Cannabinoids for Treatment of Serious Neurological and Inflammatory Conditions
Our Mission Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Our Technology In 2013, we developed a proprietary enzymatic biosynthesis production system in order to improve the taste of stevia, a natural compound used as a high-potency sweetener. This platform harnesses a naturally-occurring biological process known as glycosylation, which involves using enzymes to attach glucose (sugars) to small-molecule compounds. Over the last 10 years or so, it has become well appreciated within the pharmaceutical industry that glycosylation can act to generate new natural product libraries with improved drug properties. This platform technology enables us to readily modify existing drug compounds, especially natural products, in order to give them attractive new drug properties.
Meeting Pharmaceutical Market Demands Vitality is developing proprietary cannabinoid pharmaceuticals that are compliant with FDA and DEA regulations. Oral cannabinoid pharmaceuticals are a convenient and desirable option for patients and physicians, and they could help realize the full therapeutic potential of cannabinoid medicines.
A Low-Cost, Low-Risk Regulatory Strategy Oral prodrugs enable a regulatory strategy with lower risk that is akin to specialty pharmaceutical development. The company benefits from existing clinical studies of cannabinoids demonstrating their effectiveness in treating in IBD, NBS, MS, neuropathic pain, and additional disease indications.
Healthcare & Life Sciences Expertise Senior management is entrepreneurial with a track record in healthcare and drug development. Laboratory and manufacturing operations are based in Northern California, and the R&D team includes passionate scientists, medical advisers, and regulatory affairs specialists.
Clinical Trials & Unmet Needs Clinical Trials & Unmet Needs There is increasing recognition and acceptance from physicians and researchers that there may be vast therapeutic potential for cannabinoids, including THC and also cannabidiol (â€œCBDâ€?), which is not mindaltering. This interest has led independent research investigators to conduct a wide variety of preclinical and clinical studies to examine their therapeutic benefits, including for treatment of the disease indications.
Treatment of Inflammatory Bowel Disease Independent clinical trial results suggest that cannabinoids will help induce remission in Crohnâ€™s disease patients, even in patients who are heavily medicated and have not responded to corticosteroids, anti-TNF-alpha drugs (Remicade, Humira, etc.), or immunomodulators.
About US Vitality Biopharma is a cure development company, dedicated to unlocking the power of cannabinoids to treat serious neurological and inflammatory disorders.
Contact US Vitality Biopharma, Inc. Address: 1901 Avenue of the Stars, 2nd Floor City: Los Angeles State: CA Zip code: 90067 Country: USA Phone: (530) 231-7800 Email: email@example.com Website: http://vitality.bio Web Blog: http://vitality.bio/investors/news/ Twitter: hhttps://twitter.com/VitalityBio Facebook: https://www.facebook.com/VitalityBio Linkedin.com: https://www.linkedin.com/company/vitality-biopharma?trk=company_logo
Published on Jan 13, 2017
Vitality Biopharma is a cure development company, dedicated to unlocking the power of cannabinoids to treat serious neurological and inflamm...